• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Compounded drug may have killed four horses, FDA reports

May 15, 2014

10 horses in Kentucky and Florida affected by EPM treatment; agency is investigating.

Two lots of products compounded by Wickliffe Pharmacy of Lexington, Ky., have been associated with adverse events in 10 horses, including four deaths, the U.S. Food and Drug Administration (FDA) reports.

Seizures, fever and other clinical signs have been reported in two horses in Kentucky and eight horses in Florida that were administered compounded combination drug products containing pyrimethamine and toltrazuril, used to treat equine protozoal myeloencephalitis (EPM). Four horses have died or been euthanized and six horses are recovering.

The FDA is investigating the products, one compounded as a paste and the other an oral suspension. Testing indicates that one lot contained higher levels of pyrimethamine than the labeling indicates. Adverse events associated with high doses of pyrimethamine include seizures, fever and death.

“During the course of this ongoing investigation into the adverse reactions, it has come to the attention of FDA that elevated doses of pyrimethamine may have been used by some practitioners with negative results,” a release from the FDA states. “The usual dose of pyrimethamine in horses is 1 mg/kg, which has been shown to be safe for the treatment of EPM in an FDA-approved combination product containing pyrimethamine and sulfadiazine.”

Wickliffe Veterinary Pharmacy issued a statement May 16 stating the medication was specifically made for and dispensed to the horses for which the medication was prescribed. The pharmacy says it adheres to the highest safety and quality standards of the compounding pharmacy profession and is cooperating with federal health officials in the investigation. “We wish to extend our deepest sympathies to the owners of, and equine professionals associated with, the horses that have died or been euthanized,” the statement reads.

Advertisement

The FDA says the compounded products involved in the investigation were not made from approved animal drugs. Additionally, the FDA says, toltrazuril is not approved for use in horses at all. The FDA is encouraging veterinarians, horse owners and caretakers to report any symptoms such as seizure, fever or collapse in horses who might have received high doses of pyrimethamine.

“The FDA has serious concerns about unapproved animal drugs, including certain compounded animal drugs,” the release states. “These drugs are not evaluated by FDA and may not meet FDA’s strict standards for safety and effectiveness.”

Drugs that have been evaluated and approved by FDA for the treatment of EPM include ponazuril, diclazuril and a combination of pyrimethamine and sulfadiazine. All lots of the compounded products in question have been accounted for and are no longer in distribution.

Veterinarians and horse owners can report complaints about FDA-regulated animal drug products by calling the consumer complaint coordinator in their area or by filing a Veterinary Adverse Drug Reaction report. Information on reporting consumer complaints can be found at fda.gov.

Related Content:

RegulatoryEquine MedicineBreaking NewsEquine
LSU Vet Med plays major role in detecting toxin affecting Louisiana horses
LSU Vet Med plays major role in detecting toxin affecting Louisiana horses
First injectable pentosan for equine osteoarthritis is approved by FDA
First injectable pentosan for equine osteoarthritis is approved by FDA
Veterinarian kills 2 police officers in Mississippi
Veterinarian kills 2 police officers in Mississippi

Advertisement

Latest News

3 Must-reads for National Pet Dental Health Month

Veterinary Dentistry Specialists first to apply human fracture repair technology to companion animals

Long Island University debuts College of Veterinary Medicine Learning Center

Paving the way for a more diversified veterinary profession

View More Latest News
Advertisement